全文获取类型
收费全文 | 74304篇 |
免费 | 6413篇 |
国内免费 | 2124篇 |
学科分类
医药卫生 | 82841篇 |
出版年
2023年 | 782篇 |
2022年 | 1199篇 |
2021年 | 2574篇 |
2020年 | 1991篇 |
2019年 | 1934篇 |
2018年 | 2054篇 |
2017年 | 1852篇 |
2016年 | 1913篇 |
2015年 | 2496篇 |
2014年 | 3122篇 |
2013年 | 3615篇 |
2012年 | 5080篇 |
2011年 | 5490篇 |
2010年 | 3315篇 |
2009年 | 2963篇 |
2008年 | 4444篇 |
2007年 | 4423篇 |
2006年 | 4303篇 |
2005年 | 4172篇 |
2004年 | 3549篇 |
2003年 | 3441篇 |
2002年 | 3223篇 |
2001年 | 1020篇 |
2000年 | 986篇 |
1999年 | 1071篇 |
1998年 | 857篇 |
1997年 | 739篇 |
1996年 | 590篇 |
1995年 | 579篇 |
1994年 | 472篇 |
1993年 | 383篇 |
1992年 | 475篇 |
1991年 | 424篇 |
1990年 | 407篇 |
1989年 | 393篇 |
1988年 | 373篇 |
1987年 | 354篇 |
1986年 | 324篇 |
1985年 | 330篇 |
1984年 | 309篇 |
1983年 | 302篇 |
1982年 | 310篇 |
1981年 | 303篇 |
1980年 | 262篇 |
1979年 | 238篇 |
1978年 | 231篇 |
1977年 | 201篇 |
1976年 | 166篇 |
1975年 | 184篇 |
1974年 | 191篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
41.
42.
Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes. Therefore, it is necessary for cardiologists, patients with diabetes, and nephrologists to fully understand this type of drug. In this review, we summarize the following three aspects of SGLT2 inhibitors: the recent clinical evidence of their cardiovascular benefits, their mechanisms of action, and their safety. 相似文献
43.
44.
Chen Rong Zhang Yuan Huang Lei Cheng Bi-heng Xia Zhong-yuan Meng Qing-tao 《Journal canadien d'anesthésie》2020,67(6):655-663
Canadian Journal of Anesthesia/Journal canadien d'anesthésie - To assess the management and safety of epidural or general anesthesia for Cesarean delivery in parturients with coronavirus... 相似文献
45.
46.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
47.
Fabian M. Laage Gaupp Nadia Solomon Ivan Rukundo Azza A. Naif Erick M. Mbuguje Anish Gonchigar Minzhi Xing John D. Prologo Douglas D. Silin Frank J. Minja 《Journal of vascular and interventional radiology : JVIR》2019,30(12):2036-2040
Despite a population of nearly 60 million, there is currently not a single interventional radiologist in Tanzania. Based on an Interventional Radiology (IR) Readiness Assessment, the key obstacles to establishing IR in Tanzania are the lack of training opportunities and limited availability of disposable equipment. An IR training program was designed and initiated, which relies on US-based volunteer teams of IR physicians, nurses, and technologists to locally train radiology residents, nurses, and technologists. Preliminary results support this strategy for addressing the lack of training opportunities and provide a model for introducing IR to other resource-limited settings. 相似文献
48.
Shiyu Jiang Yan Qin Hongxin Jiang Biao Liu Jianming Shi Fanlu Meng Peng Liu Jianliang Yang Sheng Yang Xiaohui He Shengyu Zhou Lin Gui Hao Liu Jing Lin Han Han-Zhang Yuankai Shi 《International journal of cancer. Journal international du cancer》2020,147(9):2611-2620
Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a panel consisting of 112 lymphoma-related genes. Subsequently, 81 treatment-naïve patients with measurable disease and followed for over 1 year were included for survival analysis. Collectively, the most commonly seen mutations included IGH fusion (69%), PIM1(33%), MYD88 (29%), BCL2 (29%), TP53 (29%), CD79B (25%) and KMT2D (24%). Patients with TP53 mutations were more likely to have primary refractory disease (87.0% vs 50.0%, P = .009). For those with TP53 disruptive mutations, 91.7% patients were in the primary refractory group. Interestingly, BCL-2 somatic hypermutation was only seen in patients without primary refractory disease (P = .014). In multivariate analysis, BCL-2 amplification (hazard ratio [HR] = 2.94, P = .022), B2M mutation (HR = 2.99, P = .017) and TP53 mutation (HR = 3.19, P < .001) were independently associated with shorter time to progression (TTP). Furthermore, TP53 mutations was correlated with worse overall survival (P = .049). Next, we investigated mutation landscape in patients with wild-type (WT) TP53 (n = 58) and found that patients harboring MYD88 L265P had significantly inferior TTP than those with WT or non-265P (P = .046). Our study reveals the mutation spectrum of treatment-naive Chinese DLBCL patients. It also confirms the clinical significance of TP53 mutations and indicates the prognostic value of MYD88 L265P in TP53 WT patients. 相似文献
49.
目的:探讨40岁以上高龄女性体外受精-胚胎移植(IVF-ET)的妊娠结局,旨在为高龄女性提供生育咨询以及为改善高龄女性个体化辅助生殖治疗结局提供临床依据。方法:选择我院生殖中心2015年1月—2017年12月女方年龄≥40岁且使用自身卵子行体外受精的共2 467个治疗周期资料,对各项临床数据进行回顾性分析。结果:40岁及以上行辅助生殖治疗的患者,随着女性年龄增加获卵数明显减少(40~48岁女性平均获卵数分别为2.97、 2.69、2.17、2.01、1.77、1.61、1.68、1.29和1.00,44~48岁与40~43岁依次组间比较均P<0.05),尤其是44岁以上女性胚胎发育潜能明显降低(40~48岁囊胚形成率分别为48.90%、43.72%、33.67%、34.29%、24.39%、21.14%、26.32%、16.67%和0%,44~48岁与40~43岁组间依次比较均P<0.05)。共有518个周期行新鲜胚胎移植,结果显示,随女性年龄增加,临床妊娠率(40~48岁临床妊娠率分别为26.92%、21.15%、20.79%、10.96%、18.87%、11.11%、5.88%、0%和0%,43~48岁与40~42岁组间依次比较均P<0.05)、种植率(40~48岁种植率分别为23.65%、19.51%、17.70%、8.54%、7.49%、10.81%、5.56%、0%和0%,43~48岁与40~42岁组间依次比较均P<0.05)和活产率均显著降低(40~46岁活产率分别为18.46%、10.58%、9.90%、5.48%、5.66%、2.78%和5.88%,43~46岁与40~42岁组间依次比较均P<0.05),43岁以上者结局更差。44岁以上女性自然流产率明显增高(40~45岁流产率分别为31.43%、50.00%、52.38%、50.00%、70.00%和75.00%,44~45岁与40~43岁组间依次比较均P<0.05)。46岁女性仅1例妊娠并分娩,47岁和48岁女性均无成功妊娠。与抗苗勒管激素(AMH)>1.0 ng/mL组相比,AMH≤1.0 ng/mL组妊娠率、种植率及活产率均显著下降(27.04% vs. 14.74%,22.99% vs. 13.50%,15.88% vs. 7.37%;均P<0.05),流产率明显升高(41.27% vs. 50.00%,P<0.05)。结论:≥40岁高龄女性随年龄增长生育力逐渐降低。40~43岁年龄段女性助孕仍有一定的价值,尤其是卵巢仍有一定储备者(AMH>1.0 ng/mL),但44岁以上女性原则上不再建议ART助孕,对于46岁以上卵巢功能衰竭的女性强烈建议卵子捐赠或收养。 相似文献
50.